Publications by authors named "V O Dezentje"
Purpose: Palliative treatment options for HR + HER2- advanced breast cancer (ABC) patients have increased, but data is lacking about the optimal treatment sequence. We used real-world data from a comprehensive cancer center to describe applied treatment sequences and we determined treatment-related and survival outcomes.
Methods: Patients aged 18 years and older with HR + HER2- ABC treated with systemic treatment were included in this historic cohort study.
Purpose: This study aims to identify which breast cancer patients benefit from the routine use of FDG-PET/CT in a large cohort of patients scheduled for neoadjuvant systemic therapy (NST).
Methods: A total of 1337 breast cancer patients eligible for NST were identified from a retrospective database between 2011 and 2020 at a single tertiary care hospital. All patients underwent staging with FDG-PET/CT prior to NST.
Background: The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.
View Article and Find Full Text PDFBackground: The antibody-drug conjugate sacituzumab govitecan is approved for metastatic triple-negative breast cancer and has shown promising results in various other types of cancer. Its costs may limit patient access to this novel effective treatment modality.
Objective: The purpose of this study was to develop an evidence-based rational dosing regimen that results in targeted drug exposure within the therapeutic range while minimizing financial toxicity, to improve treatment access.
Article Synopsis
- - Tamoxifen is commonly used in breast cancer treatment, but how effective it is can vary significantly among patients, primarily due to differing levels of its active metabolite, endoxifen.
- - A genome-wide association study (GWAS) involving 608 women aimed to find genetic factors that influence endoxifen levels and patient survival outcomes, revealing multiple significant genetic variants.
- - The study found that certain genetic variants on chromosome 22, including those linked to the CYP2D6 gene, are strongly associated with both endoxifen concentration and relapse-free survival in breast cancer patients on tamoxifen.